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1. Introduction 
DNA-based analysis is routinely used in a wide range of genetic settings, including 
evolutionary relationship studies in biology (Kondrashov et al.), identification of 
susceptibility to common diseases in clinical diagnostics (Foy et al.) and monitoring of 
infectious diseases in microbiology (Tang et al.). Advances in DNA analysis with a view to 
the development of methods that are increasingly specific, sensitive, fast, simple, automatable 
and cost-effective are considered paramount. These demands are driving the evolution of a 
diverse range of newer technologies. Clearly, some of these developing technologies will 
offer benefits to the services provided by clinical laboratories (Reiss). 
The most promising technique is DNA microarray genotyping (McGlennen). This is a 
hybridization-based method that allows the simultaneous analysis of many polymorphisms. 
The DNA sample of interest is polymerase chain reaction (PCR) amplified to incorporate 
fluorescently labelled nucleotides and then hybridized to the array. Perfectly matched 
sequences hybridize more efficiently to their corresponding oligomers on the array and 
therefore give stronger fluorescent signals over mismatched probe-target combinations. The 
hybridization signals are quantified by high-resolution fluorescence scanning and analysed 
with computer software (Shi, Chee et al., Wang et al.). The application of these chip-based 
genotyping technologies is now under development. A number of arrays have been generated 
to detect variants in the different microbial genomes and in human polymorphism (Gershon). 
The current limitation is that homozygous variants are readily detected, whereas heterozygous 
ones may be missed and deletions and insertions will not be recognized specifically. 
Another recently described method is real-time pyrophosphate DNA sequencing 
(Alderborn et al., Aldeborn). Pyrosequencing detects the de novo incorporation of nucleotides 
based on the specific template. The incorporation process releases a pyrophosphate that is 
converted in the presence of 5'-phosphosulfate to adenosine triphosphate (ATP), which in 
turn stimulates luciferase. The light production in the luciferase-catalysed reaction is detected 
by a charge-coupled device camera. ATP and unincorporated deoxynucleotide triphosphates 
(dNTP) are continuously degraded by apyrase. The light is switched off and the next dNTP is 
added. As the process continues, the complementary DNA strand is built up and the 
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nucleotide sequence is determined from the signal peak in the program (Pyrosequencing AB, 
Uppsala, Sweden http://www.pyrosequencing.com). The major disadvantage of the method is 
the limited length of the investigated DNA (Garcin et al., O'Meara et al., Gharizadeh et al.). 
Platforms available for non-PCR-based techniques include the BDProbeTecET™ system 
(BD Biosciences, http://www.bd.com/biosciences), based on strand displacement 
amplification (Little et al.), and the Abbott LCx™ system (Abbott Laboratories, 
http://www.abbottdiagnostics.com), based on the ligase chain reaction (Austina et al.). 
Many currently used techniques rely on the PCR amplification of a target molecule, followed 
by a variety of post amplification analyses, such as restriction enzyme digestion, agarose gel 
electrophoresis or melting-point analysis, to detect the specific analyte amplified (Wolk et al.). 
One of the recent advances is the development of technologies with the ability to amplify, 
detect and quantify DNA targets in a single closed-tube reaction as the PCR proceeds. These 
real-time homogeneous systems offer many advantages over traditional methods, including 
speed, a reduced risk of contamination and the ability to quantify the amount of starting 
material present more accurately. These technologies have been used for the on-line 
quantification of nucleic acid targets, mutation detection and sequence confirmation. 
Several platforms are available for the performance of real-time PCR analyses. These range 
from ultra rapid, heated-air thermocyclers, where the PCR is performed in glass capillaries 
(Roche LightCycler, Roche Diagnostic Systems, http://www.roche.com/diagnostics), to tube 
and microtitre plate-based systems (ABI Prism 7700 Sequence Detection System, Abbott 
Laboratories, http://www.abbottdiagnostics.com). As the use of real-time PCR assays gains 
popularity, a range of alternative real-time instruments are becoming available, including the 
iCycler (Bio-Rad), the Sentinel (Stratagene), the DNA Engine Opticon (MJ Research) the 
MCA System (HYBAID) and the SmartCycler (Cepheid). 
The ABI Prism 7700 Sequence Detection System utilizes an array of optical fibres to 
distribute laser light across all 96 samples contained in either thin-walled tubes or microtitre 
plates. The fluorescence emitted returns via the fibres to a spectrograph with a charged 
coupled device camera. Fluorescence between 500 and 660 nm can be detected. The built-in 
thermal cycler usually needs 2 hours to complete the amplification of the reactions. 
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Basically two kinds of detection methods are used in real-time PCR assays. In the case of 
non-specific detection methods, dyes such as SYBR Green produce enhanced fluorescence 
signals upon binding to dsDNA duplexes. Increases in signals are monitored in real time as the 
dye binds to the newly synthesized DNA molecules as the PCR proceeds. The signals are 
measured at the end of either the annealing or elongation step of each PCR cycle. Although 
the application of dsDNA-binding dyes is a simple, fast and inexpensive way of monitoring 
amplicon production, the major disadvantage of the method is that the dye binds non-
specifically to all dsDNA and thus primer-dimer species and non-specific amplification 
products cannot be distinguished from the specific amplicon. Careful assay optimization is 
critical to minimize the production of non-specific species. Most platforms offer the 
opportunity to "melt" the amplicons after amplification is completed. If the temperature is 
increased slowly, the point at which the strands dissociate can be identified by the subsequent 
drop in signal as the dye falls from the denatured duplex (Ririe et al.). 
The specific, fluorescence probe detection methods require fluorophore-conjugated probes 
for investigation. Many probe-based systems rely on the principle of fluorescence resonance 
energy transfer (FRET) for signal generation. FRET involves the non-radiative energy transfer 
from a donor molecule to an acceptor molecule. When two fluorophores whose excitation and 
emission spectra overlap are in close physical proximity, excitation of one fluorophore will 
cause it to emit light at wavelengths that are absorbed by and stimulate the second 
fluorophore. The excited acceptor molecule releases its captured energy and returns to a lower 
energy state. The released energy can be dissipated into the environment as light or heat. Most 
of the probe-based systems, such as TaqMan™ probes (Livak et al., Chen et al.), molecular 
beacons (Giesendorf et al., Smit et al.) and Scorpion™ primers (Whitcombe et al.), use non-
fluorescent acceptors that will accept energy from a donor without any resulting fluorescence 
emission. These acceptors as a group are known as "dark quenchers", and include Dabcyl, 
QSYTM-7 and BlackHoleTM dyes. The donor dyes are generally FAM, fluorescein, TET 
HEX or TAMRA. Upon hybridization to the target, the fluorophore and quencher become 
separated, either through conformational changes that occur upon hybridization (molecular 
beacons and Scorpion primers) or through enzymatic cleavage of the fluorophore from the 
quencher upon hybridization as a result of the 5'-nuclease activity of Taq polymerase 
(TaqMan probes). The physical separation of the fluorophore and quencher moieties produces 
an increase in signal. 
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TaqMan probes consist of a probe sequence labelled at one end with a fluorophore and at the 
other end with a quencher moiety. In the unhybridized state, fluorescence is quenched because 
of the close proximity of the fluorophore and quencher. Upon hybridization of the probe to the 
target sequence during PCR, the 5'-3'-exonuclease activity of Taq polymerase cleaves the 
probe; the subsequent separation of the fluorophore from the quencher produces a 
concomitant increase in fluorescence. 
Molecular beacon probes are designed such that a target-specific hybridization domain is 
positioned centrally between short sequences (unrelated to the target). The fluorophore and 
quencher moieties are situated on the 5' and 3' ends of the probe in the native state; the 
molecular beacon forms a hairpin structure, with the reporter and quencher groups directly 
adjacent.Upon hybridization to the target sequence, the loop opens out; the resulting 
separation of the fluorophore from the quencher produces an increase in the signal. Molecular 
beacons have been reported to have a higher specificity than that of TaqMan probes, because 
of the presence of a stem structure (Tyagi et al.). Hybrids between the beacons and mismatch 
targets dissociate at lower temperatures than do hybrids between linear probes and mismatch 
targets. Thus, a wider temperature range is observed between the melting points of perfect and 
mismatch hybrids. 
Scorpion primers consist of a probe sequence linked to the 5' end of a primer via a non-
amplifiable stopper moiety. The probe is held in a hairpin loop structure by complementary 
sequences on the 5' and 3' sides of the probe. A fluorophore at the 5' end of the probe is 
quenched by a moiety at the 3' end of the loop in the unhybridized format (similar to 
molecular beacons). As the primer extends during PCR, the probe sequence is capable of 
hybridizing to a target on the newly formed strand. Upon hybridization, the loop is opened, 
producing a physical separation of the fluorophore and quencher, so that the signal increases. 
Probe-based systems can be used for both quantitative and qualitative applications (Ruitz-
Ponte et al., Rasmussen). For qualitative applications, the probes are designed to hybridize to 
the region containing the specific sequence or mutation under investigation. Amplification is 
performed by using an annealing temperature intermediate to the melting temperatures (Tm) of 
the probe on its matched and mismatched targets so that a signal will be generated only when 
the probe perfectly matches the target. In this way, the amplification and the analysis are 
finished at the same time. 
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The LightCycler utilizes a blue-light-emitting diode with fluorescence measured by three 
photodetection diodes with different wavelength filters. The capillaries are placed in a 
carousel rotated over the diodes. The ultrarapid heating and cooling of the capillaries with an 
airstream allows amplifications to be completed in typically <20 min (Wittwer et al.).The 
donor dye in the LightCycler probe-based system is either fluorescein or FAM. The 
fluorescent acceptors that accept energy from a donor to result in fluorescence emission with 
a wavelength of 640 or 705 nm are LCRed640 (or Cy5) and LCRed705 (or Cy5.5) (Wittwer). 
This probe method uses two fluorescently-labelled oligonucleotide probes. The donor and 
acceptor fluorophores are conjugated to the 3' and 5' ends of different oligonucleotides. Thus, 
they are originally separated. Additionally, any probe used in PCR must be blocked at the 3' 
end in order to prevent extension by polymerase. FRET occurs as the two probes hybridize in 
a head-to-tail arrangement to adjacent sequences on the target DNA. One of the probes is a 
tightly binding 'anchor probe', whereas the adjacent 'sensor probe' spans the region of 
sequence variation. As the reaction mixture is heated, the probe-target duplex is denatured, 
the fluorophores are separated and the fluorescence of the acceptor dye drops to the 
background. When the probe hybridizes over a sequence variant, a mismatch is formed and 
the duplex is destabilized. This is reflected as a shift in Tm, the temperature at which 50% of 
the probe is denatured. The final analysis is more easily discerned by plotting a derivative 
melting curve, where the centre of the melting peak corresponds to the point of inflection of 
the fluorescence-temperature curves. Although the temperature dependence of the detection 
probe can be observed during rapid thermal cycling (Lay et al.), a slower temperature 
transition performed as an addendum to PCR is optimum for single base discrimination. 
Hybridization probes have been used for mutation detection by both slow cooling (annealing 
curves) and slow heating (melting curves) (Gundry et al.); melting curve analysis is more 
commonly used. With the aid of two different acceptor dyes, multiple mutation detection is 
possible. 
Disease-causing mutations have been identified by means of molecular genetic techniques in 
an increasing number of genes in recent years. The incidence of 'disease genes' is accelerating 
rapidly as a result of the progress of the Human Genome Project. Since the majority of 
mutations in genetic disorders are due to single base pair changes or insertions or deletions, it 
is highly desirable to develop DNA diagnostic tests that are sensitive, specific, cost-effective 
and easily carried out in any clinical laboratory. 
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The detection of mutations in individuals who carry such gene mutations can be of 
significance as concerns early diagnosis, genetic counselling and disease prevention (Kohli-
Seth et al.).Moreover, it may be important to carry out large prospective studies in which the 
roles of the potential genetic risk factors can be examined under standardized circumstances. 
(Szolnoki et al.) 
Ischaemic stroke is considered to be a multifactorial disease (Hassan et al.). Different 
environmental and genetic factors together might lead to its development. Several genetic 
mutations and polymorphisms can be associated with stroke. 
Such presumptive mutations could have been the mutations of the thromboembolic factors. 
The most important mutations associated with the thromboembolic events are the factor V 
mutations and the factor II prothrombin G20210A mutation (Bowen et al., Zent et al.). 
Hyperhomocysteinaemia has also been shown to be a risk factor for venous thromboembolic 
diseases (Den Heier et al.). A genetic risk factor that is thought to cause a folic acid deficiency 
level that gives rise to hyperhomocysteinaemia is the methylenetetrahydrofolate reductase 
(MTHFR) C677T mutation (Frosst et al., Arruda et al.). A second common mutation in the 
MTHFR gene (A1298C) has been described which, in combination with a heterozygous 
MTHFR C677T mutation, can have a similar pathobiochemical effect to that of a 
homozygous MTHFR C677T mutation (Put et al., Cunha et al.). In this study, we investigated 
only the MTHFR C677T mutation, but, with regard to future surveys, we developed a new 
multiplex real-time PCR method capable of investigating both MTHFR mutations together 
(Somogyvâri et al.). 
In the renin-angiotensin system, angiotensin-converting enzyme (ACE) is a peptidyl 
dipeptide hydrolase that plays a role in the conversion of angiotensin I into the active 
octapeptide angiotensin II and also inactivates the vasodilator bradykinin (Hooper NM). The 
blood and cellular levels of ACE are determined genetically. The variability of the plasma 
ACE levels is a result of an I/D polymorphism of the ACE gene (Tiret et al.). The presence of 
the D allele is associated with higher circulating ACE levels and several human disorders (Lin 
et al.). 
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Apolipoproteins (Apo) play a central role in the cholesterol transport by their association to 
lipoproteins and their function as ligands for receptors. Genetic variation of the ApoE locus in 
humans is an important determining factor of plasma lipid concentrations. The E4 isoform is 
associated with increased cholesterol, thereby enhancing the risk of circulatory diseases 
(Davignon et al.). In addition, E4/E4 individuals are at high risk of the development of 
Alzheimer disease (Corder et al.). There is growing evidence of interactions between the 
renin-angiotensin system and hypercholesterolaemia (Batalla et al., Nakai et al.), and between 
the renin-angiotensin system and hyperhomocysteinaemia (Fernandez-Areas et al.) as 
concerns enhancement of the risk of different circulatory diseases. This is the 
pathobiochemical background upon which these mutations were chosen as the objects of the 
present study. 
The roles of factor V mutations such as the Leiden G1691A (Catto et al., De Lucia et al., 
Eskandari et al., Gaustadnes et al.), R306T Cambridge (Williamson et al.) and R306G Hong 
Kong (Chan et al.) in the pathogenesis of stroke are still debated. It has been reported that the 
prothrombin G20210A mutation can be detected more frequently in young patients who have 
suffered a stroke than in healthy persons (de Stefano et al, Giardano et al., Ridker et al., 
Huberfeld et al.). The Leiden and prothrombin G20210A mutations might give rise to stroke 
if they are associated with hypertension, diabetes mellitus or some other clinical risk factors 
(Huisman et al., Zenz et al.). 
The effects of ACE I/D polymorphism (Agerholm et al., Doi et al., Takami et al., Zee et al.), 
MTHFR C677T mutations (Harmon et al., Nakata et al., Press et al., Salooja et al.) and the 
ApoE genotypes (Chowdhury et al., MacLeod et al., Perdro-Botet et al., Topic et al.) in the 
pathogenesis of stroke has not yet been fully elucidated. Although all these mutations can be 
associated with arteriosclerosis or thrombophilia or vasoregulation disturbances (Bortolotto et 
al., Bostom et al., Clarke et al., Okamura et al., Perry) on a pathophysiological basis, none of 
them in themselves have been proved to be a major genetic risk factor for ischaemic stroke 
(Elbaz et al., Kontula et al.). 
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2. Aims of the study 
A correct diagnosis is essential for adequate therapy. For this purpose, the usage of new 
diagnostic methods is advisable. Molecular biology tests are currently undergoing continuous 
improvement, refinement and differentiation. The diagnostic resolution may be enhanced by 
direct analysis of genes because, besides the clinical picture, the genetic characteristics of the 
host may contribute to the aetiology and pathogenesis of different diseases. 
2.1. One of our aims was to increase the efficiency and decrease the time consumption and 
handling requirements of human genetic examinations. Efficiency is important in population 
studies, where large number of examinations should be performed. The time factor could be 
crucial at the patient level because the rapid elucidation of certain hereditary diseases might 
influence the efficacy of the therapy and the outcome of the disease. Finally, handling and 
cost-effectiveness are key issues for clinical laboratory practice. 
The genotyping procedure can generally be divided into two steps: sample preparation and 
allele detection. To accomplish this goal, we first changed the DNA extraction from a home-
brew method to use of the rapid manufactured kit. All of the previously used traditional PCR-
RFLP (restriction fragment length polymorphism) assays were then replaced with real-time 
PCR tests. In the case of ACE polymorphism, we have developed a new real-time PCR 
method. This was necessary because real-time PCR methods were originally established for 
the detection of point mutations. We could not find any publication in the literature that 
reported a method for the reliable detection of long insertions/deletions by using real-time 
PCR technology. 
In detail, the aims were as follows: 
To find a generally applicable method for the detection of different alleles with long 
insertions/deletions, using fluorescence-labelled detection probes. 
To design detection probe-pair with which to examine ACE insertion/deletion polymorphism 
with the Roche LightCycler instrument. 
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To optimize the conditions of real-time PCR reactions on use of the Roche LightCycler 
instrument: 
Optimization of the MgCh concentration 
Optimization of the dimethyl sulfoxide (DMSO) concentration 
Optimization of the annealing temperature 
Optimization of the concentrations of the primers 
Optimization of the concentrations of the detection probes 
2.2. Our second aim was to apply these methods in clinical practice. For this purpose, we 
chose to examine the genetic background of a multifactorial disease, and the possible value of 
the examinations in the therapeutic strategy. 
Our final goal was to examine the role of genetic factors in stroke cases when these factors 
were not associated with other well-known clinical risk factors. 
In detail: 
The screening of different mutations in a satisfactorily large population of stroke patients was 
performed in order to ascertain whether these genetic alterations could themselves be risk 
factors for stroke. 
The examined mutations were: 
factor V Leiden G1691A mutation 
factor V Cambridge R306T mutation 
factor V Hong Kong R306G mutation 
prothrombin G20210A mutation 
MTHFR C677T polymorphism 
ACE I/D polymorphism 
ApoE polymorphism 
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3. Patients, materials and methods 
3.1. Stroke patients 
406 stroke patients were identified by screening the medical records of the Neurological and 
Neurophysiological Department at Pándy Kálmán County Hospital in Gyula. All subjects 
underwent a detailed clinical scrutiny, including an exploration of the medical history and the 
family history, an evaluation of vascular risk factors, general physical and neurological 
examinations, urine analysis, extended laboratory examinations to detect coagulopathies such 
as deficiencies of antithrombin III, protein C and S, vasculitis, underlying infections or 
immunodeficiencies, electrocardiography, extracranial and transcranial Doppler sonography 
of the brain-supplying arteries, transthoracic and/or transoesoephageal echocardiography 
where appropriate, and magnetic resonance imaging examinations within 2 days after the first 
observation of the symptoms. 
3.2. Genetic examinations 
The genetic examinations were carried out without knowledge of the results of the clinical 
work-up. 
By means of the PCR technique, the coagulation factor V (R506Q Leiden, R306G Hong 
Kong, and R306T Cambridge), prothrombin G20210A and MTHFR C677T mutations, and 
the ACE and ApoE polymorphisms were examined. 
The R306G Hong Kong and R306T Cambridge mutation examinations were carried out in the 
Department of Human Genetics and Child Development at the University Medical School, 
Pécs, Hungary. 
A Perkin Elmer GeneAmp PCR System 2400 block thermocycler was used between 1 
January 1998 and 1 April 1999. The amplified DNA was genotyped by using restriction 
enzyme digestion. The restriction products were resolved on agarose gel. The restriction 
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patterns were enrolled on polaroid film after the visualization of bands with ethidium 
bromide. 
DNA isolation (Miller et al.) and the PCR technique for the Leiden V (Greengard et al.), 
MTHFR 677C-T (Clark et al.) and prothrombin 20210G-A mutations (Danneberg et al.) and 
ApoE polymorphism (Crook et al.) were carried out in accordance with the original 
descriptions. ACE polymorphism was examined by a modification of the original (Rigat et 
al.) description for the increased detection of heterozygotes (Chiang et al.). 
The following reagents were used: PCR mastermix, 25 mM MgCL and EdNTP (Perkin 
Elmer, Norwalk, USA), proteinase K, dimethyl sulfoxide, agarose, ethidium bromide and 
REDTaq DNA polymerase (Sigma Aldrich, Munich, Germany), and Hindlll, Hinfl and Hin6I 
(Hhal) restriction enzymes (Fermentas AB, Vilnius, Lithuania). 
The primers were synthetized in the Biological Research Centre of the Hungarian Academy of 
Sciences, Szeged. 
In order to reduce the time requirements, real-time PCR (a LightCycler™ instrument, Roche 
Diagnostics) was used after 1 April, 1999. 
At the same time, we changed the DNA extraction from a home-brew method to the rapid 
manufactured kit. Genomic DNA was extracted from 200 pi of peripheral blood 
anticoagulated with EDTA with the High Pure PCR Template Purification Kit from Roche 
Diagnostics and the QIAmp DNA Blood Mini Kit from Qiagen Incorporated, according to the 
manufacturer's instructions. 
The PCR technique for the Leiden V and prothrombin 20210G-A mutations (Berg et al.), the 
MTHFR 677C-T mutation (Ahsen et al.) and the ApoE polymorphism (Bernard et al. and 
Aslanidis et al.) was carried out in accordance with the original descriptions. 
The following reagents were used: PCR mastermix, and 25 mM MgCh (Roche, Mannheim, 
Germany). 
The primers and probes were synthetized by Tib MolBiol, Berlin, Germany. 
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The ACE polymorphism was examined by a PCR method developed with a view to 
decreasing the examination time and to providing a better detection of heterozygotes. This 
method consisted in fluorescent probe melting point analysis performed with fluorescently 
labelled oligonucleotide hybridization probes on the LightCycler™ instrument (Roche 
Diagnostics). 
3.3. Primer design 
The amplification primers were reported by Rigat et al. 
The insertion-specific confirmatory primer pair were demonstrated by Lindpaintner et al. 
The Oligo Analyzer 2.5 program was used to check the annealing temperatures of the primers. 
Use of the program is available free on the home page of Integrated DNA Technologies 
(http://www. idtdna. com/). 
The primers were manufactured by Life Technologies Ltd. (3 Fountain Drive, Inchinnan 
Business Park, Paisley, 9A4 9RF, Scotland). The Hungarian dealer is Csertex Kft., H-1035 
Budapest, Derű u. 8. 
3.4. Probe design 
The National Center for Biotechnology Information (NCBI) home page was utilized to collect 
the sequence information (http://www.ncbi.nlm.nih.gov/). 
The ACE gene sequence (GenBank accession number AF118569) was applied to design the 
FRET probe because the antisense primers are over the 3' end of the sequence demonstrated 
by Rigat et al. (GenBank accession number X62855). 
The Qiagen Operon Oligo Toolkit (http://www.operon.com/oligos/toolkit.php) was used to 
calculate the melting temperatures of the probes. 
The probes were manufactured by Tib MolBiol Syntheselabor (Tempelhofer Weg 11-12, D-
10829 Berlin, Germany). The Hungarian dealer is Roche Hungary Kft., H-1123 Budapest, 
Győri u. 20. 
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4. Results 
4.1. The genotyping procedure 
The purity of the prepared DNA differed if we used the HighPure, the Qiagene kits or the 
salting-out procedure. The OD 260/280 was 1.5-1.6, 1.7-1.8 and 1.8-1.9 respectively. 
To perform an analysis of the ACE gene sequence (GenBank accession number AF118569), 
we designed a detection probe specific for the 3' end of the insertion (underlined four bases in 
the 5' end of the probe): 5'-CGT GAT ACA GTC ACT TTT ATG-3'. The probe was labelled 
at the 3' end with fluorescein. The designed anchor probe (5'- GGT TTC GCC AAT TTT 
ATT CCA GCT CTG -3') was labelled with LightCycler Red 640 at the 5' end and was 
modified at the 3' end by phosphorylation to block extension. There was a 1 bp gap between 
the detection and the anchor probe. 
For the amplification, we used the original primer pair described by Rigat et al. 
The relative placements of the primers and the hybridization probes detecting the ACE gene 
insertion/deletion polymorphism are shown in Figure 1. 
mutation p r o b e ( F L U J ( LCRed J anchor probe 
ACE for ACEval for 
5'-OGDSatacagtcacttttatg ggtttcgccaattttattccagctctg-3'-EHO 
. ctgctgcctATACA ACAGQOGTCatacagtcacttttatgtggtttcgccaattttattccagctctgaaa 
ACE rev ACEval rev 
Figure 1. 
(The insertion is indicated by capital letters and by the chopped line; ACE for/rev: ACE 
primers, amplicon length 490 bp with, and 190 bp without insertion; ACEval for/rev: ACE 
insertion-specific primer pair, amplicon length 335 bp only in the presence of an insertion; the 
site of the mismatch in the case of the D allele is underlined.) 
The LightCycler differs in the optimum PCR parameters from the block PCR. Consequently, 
we had to optimize the PCR reaction. 
The MgCh concentration was examined in 0.5 mM steps in the range 1-3 mM. The optimum 
was found to be 2 mM. 
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The DMSO concentration was tested in 2.5 % steps in the range 0-12.5%. The optimum was 
5%. 
The calculated annealing temperature of the forward primer used was 61.8 °C. 
The calculated annealing temperature of the reverse primer used was 61.3 °C. 
The annealing temperature tests ranged between 56 and 65 °C, in 1 °C steps. Empirically, we 
found the optimum annealing temperature to be 61 °C. 
The optimization studies were repeated with the iCycler. (Special thanks are expressed to 
József Paulik, BioRad Hungary Kft.) This is a conventional block PCR with temperature 
gradient capabilities. The gradient used ran from 55 to 65 °C. The optimum temperature here 
too proved to be 61 °C. 
The primer concentration was optimized in 3 steps between 0.1 and 0.3 pM/L. The optimum 
was 0.2 pM/L, in accordance with Rigat et al. 
The probe concentration was optimized in 5 steps between 0.05 and 0.25 pM/L. The optimum 
was 0.1 pM/L. Here, the criteria for optimum performance were the peak heights of the 
derivative melting curves and the ratio between the peaks characteristics of the two alleles. 
4. 2. Patients' description 
406 Hungarian patients diagnosed with acutely developing ischaemic stroke were examined. 
The typical risk factors included any of the following conditions: diabetes mellitus, 
hypertension, ischaemic heart disease, cardiac valvular disease, cardiac arrhythmia, cardiac 
failure, stenosis of the internal carotid artery or vertebral artery, arterial dissection, 
atherosclerotic plaques in the internal carotid artery and vertebral artery, aneurysm diseases, 
age above 60 years, hypertriglyceridaemia, hypercholesterinaemia, presence of anticardiolipin 
antibody or lupus anticoagulant, heavy smoking or drinking. 
After a detailed clinical analysis, 5 patients were found to have no classical clinical risk 
factors. No clinical explanation for the aetiology of stroke could be established in these 
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subjects. In these 5 cases, the results of clinical examinations were as follows: carotid, 
vertebral duplex and cardiac transoesophageal ultrasonography provided negative results. A 
right to left cardiac shunt could be excluded by means of an injection of agitated saline during 
the transoesophageal echocardiogram. Ultrasound examinations screening the lower 
extremities for deep vein thrombosis were negative. 24-hour arterial blood pressure 
monitoring did not register abnormal values. Magnetic resonance angiography did not reveal 
any vascular anomalies. The transcranial Doppler did not indicate any embolic events. ECG 
examinations demonstrated no rhythmic alterations. Myeloproliferative disorders, malignancy 
and complications of chemotherapy were not present. Both abdominal ultrasonographic and 
chest X-ray findings were negative. Routine blood tests and urine analyses presented normal 
values. Routine cerebrospinal fluid analyses showed no alteration. Oligoclonal bands were 
negative. Routine fungal and mycobacterium cultures of cerebrospinal fluid were negative. 
The serum immunoglobulin A, G and M levels were normal. Anticardiolipin, antileukocyte, 
antimitochondrial, anti-DNA antibody and lupus anticoagulant were not detected. Protein C, 
protein S and antithrombin deficiencies were not found. The antithrombin III levels were in 
the normal range. 
An activated protein C resistance was discovered in all 5 patients. 
Heterozygous Leiden V mutations were detected in all 5 patients. The R306T Cambridge, 
R306G Hong Kong and prothrombin G20210A mutations were not observed in any of the 5 
subjects. Heterozygous MTHFR C677T mutations were detected in patients 1-4, and the 
homozygous MTHFR C677T mutation in patient 5. I/D genotypes were detected for ACE 
polymorphism in patients 1-4, and D/D genotype in patient 5. ApoE 3/3 genotypes were 
found in all 5 subjects. 
Among the 406 stroke patients, R306T Cambridge, R306G Hong Kong, homozygous Leiden 
V and homozygous prothrombin G20210A mutations were not detected. The frequencies of 
heterozygous Leiden V mutations was 5%, that of heterozygous prothrombin G20210A 
mutations was 1%, those of homozygous and heterozygous MTHFR C667T mutations were 
11% and 31%, respectively; and the distribution of the DD, II and ID genotypes was 32%, 
23% and 45%, respectively. The frequency of the ApoE 2 allele was 7%, and that of the ApoE 
4 allele was 25%. 
5. Discussion 
5.1. The genotyping procedure 
We compared two rapid DNA extraction methods to replace the tedious and time-consuming 
salting-out procedure. The kits used were the High Pure PCR Template Purification Kit from 
Roche Diagnostics and the QIAmp DNA Blood Mini Kit from Qiagen Incorporated. The 
purity of the prepared DNA was better with the Qiagen kit, and we therefore used this. 
There were no essential problems in the application of the described real-time methods in the 
LightCycler. However, detection of the Leiden V and the prothrombin mutations did not 
succeed in the multiplexed mode as described by Berg et al., and we changed the MgCL 
concentration in the case of the MTHFR C677T mutation, and we had to combine the primers 
and the probes from two papers (Bernard et al. and Aslanidis et al.) in the case of ApoE 
polymorphism because information obtainable from the publications separately was not 
enough to emulate the described techniques successfully. 
In the case of the ACE polymorphism, we developed a new detection mode. 
The PCR method reported by Rigat et al. was considered; this presents several problems. It 
has been modified several times (Shangmugam et al., Weissensteiner et al., Chiang et al.) 
because of the preferential amplification of the D allele. The I/D heterozygotes were earlier 
mistyped as D/D homozygotes. The extent of this misclassification has been estimated at ~5% 
(Lindpaintner et al., Singer et al., Ueda et al.). One good solution to solve this problem is to 
use a second, independent PCR amplification (Lindpaintner et al.) with a primer pair 
recognizing an insertion-specific sequence. In this way, the I/D genotypes that were mistyped 
as D/D in the first PCR reaction can be detected. Unfortunately, this method is time-
consuming and laborious. 
We attempted using real-time PCR with the non-specific SybrGreen dye as this was published 
later (Lin et al., Sakai et al.), but the detectability of the I allele of the heterozygotes was not 
superior to the agarose or acrylamide gel assay. 
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For the detection of a long insertion, a possible general solution could be the design of a probe 
to overlap 1-5 bases on the insertion. The sensitivity of the detection is known to be better 
when specific probes are used, and we therefore designed and constructed one for this 
purpose.The fluorescence hybridization probe was constructed to fit in the insertion-specific 
sequence, which can be amplified by the confirmatory primer pair described by Lindpaintner 
et al. This proved to be a useful way to adapt an independent second PCR method to the 
LightCycler. 
With our specific probe, we were readily able to detect I/D heterozygosity and differentiate 
between D/D and I/D genotypes. During optimization of the new assay system, however, 
another complication arose, which forced us to modify the original method described by Rigat 
et al. further. Using the "nearest neighbour" approach (Ahsen and Schütz, Ahsen et al. 2000, 
Ahsen et al. 2001) for determination of the annealing temperature, we calculated it to be 61 °C 
instead of 58 °C, as indicated in the source article. When the experimental trial was performed 
on the optimization of the annealing temperature, it proved that the later estimation was 
correct. 
We determined the reliability of the new assay system by comparing it with the Lindpaintner 
method modified for the LightCycler. In 103 independent tests, we found no differences 
between the parallel results obtained with the two techniques. 
5.2. Patients' description 
In the published clinical studies, the allele frequency of the Leiden mutation in different 
European areas has been estimated to be 4-7% (Bowen et al, Hoppe et al., Rees et al., 
Schroder et al.), and the allele frequency of the prothrombin G20210A mutation as 1-2% 
(Cumming et al., Swibertus et al., Szén et al.). In the case of the MTHFR C677T mutation, the 
allele frequency is 36-38% in the Caucasian population (Bowen et al., Lachmeijer et al., 
Schindler et al., Somogyväri et al.), and likewise in the Japanese (Arai et al.) and French-
Canadian (Frosst et al.) populations. The frequency of the ACE D allele was found to be 44% 
(Fatini et al., Lindpaintner et al., Malik et al.) in studies on large numbers of patients 
(n>1000), and 36% (Barnas et al.) when a low number of cases were tested (n=40). In our 
studies on the frequencies of these mutations we obtained that were very similar, to those 
reported for different allele frequencies in the cited studies. 
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Very heterogeneous data have been given for different ApoE allele frequencies: in different 
papers ApoE2 allele frequencies of 2-20%, and ApoE4 allele frequencies of 6-16% (Batalla et 
al, Nakai et al, Szalai et al., Traykov et al., Tsuboi et al.). We found an even higher allele 
frequency (25%) for the E4 isoform in stroke patients. 
There are no data on the incidences of R306G Hong Kong and R306T Cambridge mutations 
in the Caucasian population. We did not observe these mutations in any of our stroke patients. 
This fact, in combination with the above observations, points to the conclusion that these 
mutations probably do not play any significant role in the pathogenesis of stroke. 
In our study, 406 patients were examined because of ischaemic stroke. After a detailed 
clinical scrutiny, 5 were found who did not exhibit any classical clinical risk factors. The aim 
of the compilation was to create a clinically homogeneous subgroup in which the role of the 
previously mentioned genetic factors in the aetiology of stroke could be analysed. 
Heterozygous Leiden V mutations, MTHFR 677T and ACE D allele were found in all 5 
stroke subjects without conventional risk factors. This type of clustering of the mutations was 
not observed in the remaining 401 stroke patients. According to the allele frequencies 
discussed above, the probability of the simultaneous presence of these three mutations in one 
person is calculated to be only 0.36-1.4%. In our 5 young stroke patients who did not carry 
any classical clinical risk factors, the frequency of the Leiden V mutations was 100%, 
whereas the occurrence of the Leiden V mutations in our overall examined stroke population 
was 5%. 
The PCR technique and the mutation pattern analysis could provide more exact data related to 
the pathogenesis of stroke. On the basis of our results, the possibility of a Leiden mutation in 
patients with ischaemic stroke should be considered when no other aetiology is evident. The 
contributions of the MTHFR C677T mutation and ACE I/D polymorphism to a thrombotic 
event (not as major risk factors, but as risk-augmenting ones) should also be kept in mind 
under such these circumstances. The presented cases suggest that it might be important to 
carry out large prospective studies in which the roles of all potential genetic risk factors 
should be examined together under standardized circumstances in special subgroups of 
patients of different ages. For such a purpose, the application of the real-time PCR technique 
appears to be convenient and excellently suitable with the methodology elaborated in our 
laboratory and presented here. 
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6. Conclusions 
6.1. We have replaced the time-consuming and laborious PCR-RFLP mutation analysis 
methods with real-time PCR tests in the cases of consequential mutations such as the factor V 
Leiden G1691A and the prothrombin G20210A mutations, and the MTHFR C677T and ApoE 
polymorphisms. 
In the case of ACE I/D polymorphism, we have constructed a new method based on 
fluorescence-labelled oligonucleotide hybridization probes and subsequent fluorescent probe 
melting point analysis. This method is more sensitive and exact than the previous ones for the 
detection of I/D heterozygotes. This procedure appears generally suitable for the detection of 
long insertions with the help of fluorescence-labelled detection probes, although the original 
recommendation is to use them for the detection of point mutations. 
6.2. The aetiological role of common genetic mutations was analysed in a subgroup of stroke 
patients. The results suggest that the Leiden mutation might possibly be a major aetiological 
factor for stroke in a rare subgroup of patients where none of the classical risk factors could 
be found. The pathogenetic roles of ACE D polymorphism and the MTHFR C677T mutation 
should also be taken into consideration in this particular subgroup of stroke patients. These 
unfavourable genetic features might be considered to be aetiological factors if they are 
clustered together in a stroke patient who does not presenting any classical clinical risk 
factors. 
Among the 406 stroke patients, the allele frequencies of the factor V Leiden and prothrombin 
G20210A mutations and the MTHFR C677T, ACE I/D and ApoE polymorphisms were 
similar to those described in previous studies. The R306G Hong Kong and R306T Cambridge 
mutations could not be detected in any of our examined subjects. 
These data demonstrate the value of these molecular genetic examinations in facilitating an 
understanding of the aetiology and pathogenesis of stroke. In the future, it might become 
possible to predict the relative risk of a stroke event in subgroups of patients by using the 
genetic allele pattern results 
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